Tazverik Archives -

News/ News/ News/ Oncology/ Sales and Marketing

Ipsen beefs up in oncology, buying US biopharma Epizyme

Phil Taylor Epizyme, Ipsen, M&A, Oncology, Tazverik 0 Comment

The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its

Ipsen beefs up in oncology, buying US biopharma Epizyme

https://pharmaphorum.com/news/ipsen-beefs-up-in-oncology-buying-us-biopharma-epizyme/

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

News/ News/ Oncology

Epizyme scores important follicular lymphoma approval with Tazverik

Richard Staines cancer, Epizyme, follicular lymphoma, R&D, Tazverik 0 Comment

Epizyme has scored an important FDA win after the regulator approved its Tazverik (tazemetostat) in follicular lymphoma. Tazverik is already approved in

Epizyme scores important follicular lymphoma approval with Tazverik

https://pharmaphorum.com/news/epizyme-unlocks-more-sales-with-tazverik-follicular-lymphoma-approval/

News/ News/ Oncology

Epizyme eyes lucrative use for newly-launched Tazverik

Richard Staines cancer, Constellation Pharmaceuticals, fda, follicular lymphoma, non-Hodgkin lymphoma, Pfizer, tazemetostat, Tazverik 0 Comment

US biotech Epizyme is gearing up for a potentially lucrative second indication for its Tazverik (tazemetostat), after the

Epizyme eyes lucrative use for newly-launched Tazverik

https://pharmaphorum.com/news/epizyme-eyes-lucrative-use-for-newly-launched-tazverik/

Trending

Tazverik

Login